OSUR Earnings Prediction
The chart below shows how OSUR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, OSUR sees a +1.03% change in stock price 10 days leading up to the earnings, and a +5.15% change 10 days following the report. On the earnings day itself, the stock moves by -0.05%. This data can give you a slight idea of what to expect for the next quarter's release.
OSUR Key Earning Data
OSUR Earnings Analysis
Positive
Strong Q1 Revenue Performance: Revenue in Q1 was in the top half of guidance range for both total revenue and core revenue.
Diagnostics Revenue Increase: Diagnostics revenue grew 8% year-over-year, driven by international business and initial orders for WHO PQ listed hepatitis C self-test.
Molecular Diagnostics Expansion: Integration of Sherlock Biosciences is progressing well, expanding OTI's product pipeline with molecular diagnostics innovation.
HCV Self-Testing Initiative Success: Successful pilot with a national health ministry in Africa for HCV self-testing programs expected to lead to similar initiatives in other countries.
Customer Loyalty and Trust: Myriad Genetics and Fulgent Genetics renewed their agreements, demonstrating customer loyalty and trust in OTI's products.
In-sourcing Manufacturing Progress: Transition to in-sourcing manufacturing of SMS products is ahead of schedule, expected to be substantially complete by the end of Q2.
Stock Repurchase Authorization: Board authorized the repurchase of up to $40 million of common stock, aligning with capital deployment strategy.
Microbiome Extraction Product Launch: New microbiome extraction products scheduled for release in June, designed to meet diverse extraction needs in research and clinical applications.
Cervical Cancer Screening Device: Colli-Pee urine collection device is progressing towards FDA clearance in 2025, supporting at-home cervical cancer risk screening tests.
Financial Stability and Growth: Strong balance sheet with zero debt and $248 million in cash and cash equivalents, providing financial stability for future growth.
Negative
Core Revenue Decline: Core revenue decreased 2% year-over-year, indicating a decline in overall business performance.
Revenue Decline in Genomics: Sample Management Solutions revenue decreased 16% year-over-year, primarily due to disruption at a large customer in the Consumer Genomics segment.
Program Revenue Decline: The Together Take Me Home program, which generated $8 million in 2024, is expected to drop to approximately $4 million in 2025 due to funding cuts, impacting revenue significantly.
Operating Loss Challenges: Operating loss in Q1 was $17.8 million, highlighting ongoing financial challenges despite revenue generation.
Negative Operating Cash Flow: Operating cash flow was negative $19.7 million, indicating cash outflow and potential liquidity concerns.
Public Health Funding Uncertainty: Uncertainty in funding for public health initiatives and NIH budgets is affecting growth prospects and customer ordering patterns.
Impact of Business Exit: The exit from the risk assessment testing business is expected to impact revenue, with $1.4 million generated in Q1 from this segment before divestment.
OSUR FAQs
How does OSUR typically perform around its earnings report dates?
OSUR's stock performance around earnings reports can vary, but historical data shows specific patterns, such as a +1.04% change leading up to the report and a +5.15% change in the 10 days following the release.
Is OraSure Technologies Inc (OSUR) Q1 2025 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
OSUR Earning Call Sentiment
OraSure Technologies, Inc. (OSUR) Q1 2025 Earnings Call Transcript
OSUR.O
-3.46%
